• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

riccardo.dolcetti@unimelb.edu.au

Credentials


Position
Head, Translational and Clinical Immunotherapy
Department of Microbiology and Immunology
Education

Not Provided
ORCID

0000-0003-1625-9853

Prof Riccardo Dolcetti

Head, Translational and Clinical Immunotherapy
Department of Microbiology and Immunology

395 Scholarly works
9 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Abstract 7701: Potential clinical utility of small extracellular vesicles derived from head and neck tumors
    DOI: 10.1158/1538-7445.am2026-7701
  • 2026

    Journal article

    Potential clinical utility of small extracellular vesicles derived from head and neck tumours
    DOI: 10.1002/VIW.20250081
  • 2026

    Journal article

    Cover Picture: Potential clinical utility of small extracellular vesicles derived from head and neck tumours (View 1/2026)
    DOI: 10.1002/viw2.70137
  • 2025

    Journal article

    Development of a circulating tumour cell culture model from head and neck squamous cell carcinoma
    DOI: 10.1002/VIW.20250085
  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Off-the-Shelf Circular mRNA Vaccine Exploiting Non-Conventional Tumour Antigens to Improve Immunotherapy of Mismatch Repair-Proficient Colorectal Cancer
  • 2023

    Research grants (ARC, NHMRC, MRFF)

    RNA Powered Antiviral Antibodies
  • 2023

    Research grants (other domestic)

    Targeting Novel Classes of Tumour Antigens in BRCA-deficient Breast Cancer to Improve Immunotherapy Responses and Overcome Resistance
Riccardo Dolcetti

RECENT SCHOLARLY WORKS

  • 2025

    Conference Proceedings

    210. Development of novel immunotherapy-based therapies in oesophageal adenocarcinoma by harnessing tumour neoantigens
    DOI: 10.1093/dote/doaf061.314
  • 2025

    Journal article

    Cryptic but critical: non-canonical antigens in cancer immunotherapy
    DOI: 10.1016/j.it.2025.06.002
  • 2025

    Journal article

    Reduced HLA-I Transcript Levels and Increased Abundance of a CD56dim NK Cell Signature Are Associated with Improved Survival in Lower-Grade Gliomas
    DOI: 10.3390/cancers17091570
  • 2025

    Journal article

    CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers
    DOI: 10.1038/s41388-024-03259-y
  • 2025

    Journal article

    Abstract A118: Targeting Replication Stress Promotes Anti-tumour Immune Responses that are Suppressed by Tumour-associated Myeloid cells
    DOI: 10.1158/2326-6074.io2025-a118
  • 2025

    Journal article

    Transcriptional signature of CD56bright NK cells predicts favourable prognosis in bladder cancer
    DOI: 10.3389/fimmu.2024.1474652

RECENT PROJECTS

  • 2025

    Research grants (ARC, NHMRC, MRFF)

    Advancing Differentiation Therapy and Immunotherapy for Paediatric High-Grade Gliomas Through Targeted Epigenome Regulation
  • 2022

    Research grants (other domestic)

    New Strategies to Improve Personalized Immunotherapy of Breast Cancer.

We acknowledge and pay respect to the Traditional Owners of the lands upon which our campuses are situated

Read about our commitment to reconciliation  

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia


View all Campus locations  
facebookIconlinkedinIconinstagramIcontwitterIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy  |  VaxFACTS

CRICOS number: 00116K     ABN: 84 002 705 224